Neuronoff Secures 5 Million Dollar Funding from US Department of Defense and National Institutes of Health
US-based medical technology company Neuronoff has announced that it has secured funding of $5 million from the US Department of Defense (DOD) and the National Institutes of Health (NIH), bringing the total secured funding to $9.1 million.
The DOD has proposed $1.73 million for a clinical trial focused on treating neurogenic bladder following spinal cord injury (SCI). In contrast, the NIH has granted $3.2 million for preclinical research into overactive bladder treatment using Neuronoff's Injectrode technology.
The funding will enable a three-year randomised controlled trial in partnership with the University of Texas Health Science Center in Houston, Texas, which will evaluate the efficacy and safety of the Injectrode device when implanted along the tibial nerve in individuals with SCI. The trial aims to assess the Injectrode's mechanisms of action in treating neurogenic bladder.
Neuronoff has already completed the first implants of its Injectrode device in a first-in-human study for chronic pain management last year, and this latest funding injection marks an important milestone in the company's mission to develop micro-invasive neuromodulation therapies for chronic conditions.
"We appreciate the continued state and federal investment in developing micro-invasive neuromodulation therapies for chronic conditions," said Dr Manfred Franke, Neuronoff CEO. "Currently, neurostimulation is primarily a 'therapy of last resort' due to invasive surgical requirements and associated costs."
The successful funding of this trial demonstrates Neuronoff's commitment to addressing key unmet medical needs in the field of spinal cord injury treatment.
Details:
- Funding: $5 million (DOD) + $3.2 million (NIH)
- Clinical Trial Focus: Treating neurogenic bladder following SCI
- Partner Institution: University of Texas Health Science Center, Houston, TX
- Total Secured Funding: $9.1 million